Profile: Derma Sciences Inc (DSCI.OQ)

DSCI.OQ on NASDAQ Stock Exchange Capital Market

8.92USD
18 Dec 2014
Price Change (% chg)

$0.37 (+4.33%)
Prev Close
$8.55
Open
$8.66
Day's High
$8.95
Day's Low
$8.66
Volume
36,454
Avg. Vol
25,555
52-wk High
$15.50
52-wk Low
$7.89

Search Stocks

Derma Sciences, Inc. (Derma Sciences), incorporated on September 10, 1984, is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. pharmaceutical wound care, advanced specialty medical device/pharmaceutical company with a primary focus on wound care. The Company has one pharmaceutical wound care product candidate that has completed a Phase 2 study and is working towards initiation of a Phase 3 study in 2012. The majority of its products are sold through distributors to various health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians’ offices. Some of its products are sold through retail channels. The Company markets its products principally through direct sales representatives in the United States, Canada and the United Kingdom, and through independent distributors within other select international markets. Its principal manufacturing facility is located in Toronto, Canada and Nantong, China. In April 2012, it acquired MedEfficiency, Inc. Effective September 4, 2013, Derma Sciences Inc acquired a 7.3% stake in Comvita Ltd, a manufacturer and wholesaler of natural health products.

Advanced Wound Care

Medihoney is a line of patented dressings, comprised of a high percentage of Active Leptospermum Honey. This type of honey has been shown to result in durable antimicrobial, anti-inflammatory and immunomodulatory activities. Medihoney dressings are ideal for the management of non-chronic and hard-to-heal wounds including chronic ulcers, burns and post-operative wounds. The dressings are non-toxic.

Bioguard is a line of patented barrier dressings that contain an active antimicrobial compound. This compound, a cationic biocide, is intrinsically bound to the dressing through a process resulting in the inability for the compound to separate from the dressing. Algicell is an antimicrobial dressing utilizing ionic silver as its active ingredient. The dressing can absorb up to 20 times its weight in wound fluid. Xtrasorb is a line of dressings that utilizes super absorbent polymer technologies. Xtrasorb dressings convert fluid within the dressings to a gel, thus locking the exudates into the dressings.

TCC-EZ is a patented advanced dressing system for the management of diabetic foot ulcers. It is considered a total contact casting (TCC) system. TCC-EZ eliminates these issues as it can be applied in less than one third the time of a traditional TCC.

Traditional Wound Care

The Company’s traditional wound care line consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices. The Company also manufactures and markets a line of adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. The Company manufactures private label wound care and adhesive bandages for a number of United States and international customers.

Private Label/OEM

The Company manufactures private label wound care and adhesive bandages. These products are used for a number of United States and international customers.

Pharmaceutical Wound Care

The Company is developing DSC127, an angiotensin analog licensed from the University of Southern California in November 2007, for use in wound healing and scar reduction. The compound has shown activity in these areas in pre-clinical animal model testing. The compound has successfully completed a Phase 1 study on healthy patients and a Phase 2 study on patients with diabetic foot ulcers.

Wound Closure and Specialty Securement Devices

The Company markets a line of wound closure strips, nasal tube fasteners and a variety of catheter fasteners to doctors, clinics, nursing homes, hospitals and other institutions. Its specialty securement and closure device products incorporate polyamide fabrics in combination with a pressure sensitive skin-friendly adhesive. These product combinations result in an ideal balance between elasticity and adherence, making the products in their ability to safely hold devices in place on the skin while assisting with the closure of sensitive areas of the skin where a cosmetic outcome is a priority. It also markets a line of traditional rigid wound closure strips.

The Company competes with Covidien, Medical Action, Convatec, Smith & Nephew, MoInlycke and Systagenix, Johnson & Johnson, Medline, ASO, Dynerex, 3M, Medicom and Medical Mart.

Company Address

Derma Sciences Inc

SUITE 300
214 CARNEGIE CENTER
PRINCETON   NJ   08540
P: +1609.5144744

Search Stocks